We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Referee needed

22 November 2010 By Robert Cyran

The two companies can t agree on a price, so the idea of a future payout based on the eventual success of a key drug sounds appealing. But contingent value rights are best suited to outcomes with a neutral referee, like a drug regulator. Otherwise, they are too easily gamed.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)